☆ 4.7 Editorial Material

Deutetrabenazine for Treatment of Chorea in Huntington Disease

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

卷 316, 期 1, 页码 33-35

出版社

AMER MEDICAL ASSOC

DOI: 10.1001/jama.2016.8011

关键词

-

类别

Medicine, General & Internal

资金

NIA NIH HHS [R01 AG AG031189] Funding Source: Medline

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Pharmacology & Pharmacy

Real-World Experience With Deutetrabenazine for Huntington Disease Chorea

Kendall Curtis, Victor Sung

Summary: Huntington disease (HD) is a hereditary neurodegenerative disorder characterized by chorea. Deutetrabenazine is an effective and well-tolerated treatment for HD-associated chorea, with a longer half-life and reduced plasma fluctuations compared to tetrabenazine.

JOURNAL OF CLINICAL PHARMACOLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Genetic screening for Huntington disease phenocopies in Sweden: A tertiary center case series focused on short tandem repeat (STR) disorders

Martin Paucar, Jose Laffita-Mesa, Valter Niemela, Helena Malmgren, Inger Nennesmo, Kristina Lagerstedt-Robinson, Magnus Nordenskjold, Per Svenningsson

Summary: Screening of a Swedish cohort revealed two cases of SCA17, one case of IPD associated with 5-OPRI, but no nucleotide expansions in C9orf72 or HDL2, SCA2 or SCA3. In addition, two sporadic cases were diagnosed with SGCE-myoclonic-dystonia and benign hereditary chorea. Whole exome sequencing identified a variant of unknown significance in STUB1 in two patients with predominant cerebellar ataxia.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2023)

添加到收藏夹

Article Clinical Neurology

A series of cases with Huntington-like phenotype and intermediate repeats in HTT

Antia Reguera Acuna, Esther Suarez San Martin, Ciara Garcia Fernandez, Santiago Fernandez Menendez, Marta Blazquez Estrada, Manuel Amorin Diaz, Manuel Menendez Gonzalez, Victoria Alvarez Martinez

Summary: This study reviewed 14 cases of Intermediate Alleles (IAs) in the HTT gene, most of which exhibited some form of extrapyramidal symptoms. Cognitive and/or behavioral symptoms were also common in these cases.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

添加到收藏夹

Article Clinical Neurology

The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study

Samuel Frank, Claudia Testa, Mary C. Edmondson, Jody Goldstein, Elise Kayson, Blair R. Leavitt, David Oakes, Christine O'Neill, Christina Vaughan, Jacquelyn Whaley, Nicholas Gross, Mark Forrest Gordon, Juha-Matti Savola

Summary: This study evaluated the long-term safety and tolerability of deutetrabenazine for the treatment of Huntington disease. The results showed that adverse events observed with long-term deutetrabenazine exposure were consistent with previous studies. Reductions in chorea persisted over time and there was no unexpected worsening of chorea upon treatment cessation.

CNS DRUGS (2022)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial

Erin Furr Stimming, Daniel Claassen, Elise Kayson, Jody Goldstein, Raja Mehanna, Hui Zhang, Grace S. Liang, Dietrich Haubenberger

Summary: Valbenazine was evaluated as a treatment for chorea associated with Huntington's disease, and it was found to be more effective than placebo in improving chorea symptoms and well tolerated.

LANCET NEUROLOGY (2023)

添加到收藏夹

Review Health Care Sciences & Services

Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington's Disease and Tardive Dyskinesia

Samuel Frank, Aljoharah Alakkas

Summary: Deutetrabenazine (DTBZ) is a safe and effective drug for the treatment of tardive dyskinesia and chorea in Huntington's Disease.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2023)

添加到收藏夹

Article Psychology, Clinical

deutetrabenazine for the treatment of chorea associated with Huntington's disease

Harshit Gupta, Wil Perkins, Cain Stark, Sathya Kikkeri, Juyeon Kakazu, Adam Kaye, Alan Kaye

Summary: This article provides a comprehensive review of the use of Deutetrabenazine in treating chorea associated with Huntington's disease. Deutetrabenazine is thought to work by inhibiting the release of monoamines, including dopamine, in the synaptic cleft. Although studies have shown mixed results, further research is needed to fully understand the potential of this drug.

HEALTH PSYCHOLOGY RESEARCH (2022)

添加到收藏夹

Article Psychiatry

Case Report: Deutetrabenazine as an Adjunctive Treatment for Stuttering

Catherine A. Ha, Gerald A. Maguire

Summary: Childhood-Onset Fluency Disorder (Stuttering) is a neurodevelopmental disorder that disrupts normal speech fluency and rhythm. While there is currently no FDA-approved treatment for stuttering, second-generation antipsychotics have shown effectiveness in reducing symptoms. However, these medications may come with metabolic side effects and movement disorders. Deutetrabenazine, a potential candidate for stuttering treatment, acts by reducing dopamine activity without the risk of metabolic adverse events.

FRONTIERS IN PSYCHIATRY (2021)

添加到收藏夹

Article Genetics & Heredity

Missing the pathological expansion in Huntington disease: de novo c.51C>G variant on the expanded allele causing intrafamilial allele dropout

Stefania Magri, Lorenzo Nanetti, Alessia Mongelli, Elena Rizzo, Franco Taroni, Caterina Mariotti, Cinzia Gellera

Summary: The study described a patient with the phenotype of Huntington disease, finding through genetic testing in family members that several other individuals in the family were affected. The disease is caused by a pathological expansion of more than 35 CAG/CAA repeats in the HTT gene, leading to the manifestation of motor, behavioral, and cognitive symptoms.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2021)

添加到收藏夹

Article Clinical Neurology

Mutation analysis of the TATA box-binding protein (TBP) gene in Russian patients with spinocerebellar ataxia and Huntington disease-like phenotype

Ekaterina Ivanova, Evgenii Nuzhnyi, Natalia Abramycheva, Sergey Klyushnikov, Ekaterina Fedotova, Sergey Illarioshkin

Summary: SCA17 is a relatively rare cause of progressive disorders with ataxia and chorea among Russian patients, characterized by core symptoms of progressive cerebellar ataxia, dysarthria, and movement disorders. Most cases are sporadic, highlighting the importance of considering SCA17 in genetic testing for patients with spinocerebellar ataxia and chorea.

CLINICAL NEUROLOGY AND NEUROSURGERY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Mitochondrial Bioenergy in Neurodegenerative Disease: Huntington and Parkinson

Annalisa Tassone, Maria Meringolo, Giulia Ponterio, Paola Bonsi, Tommaso Schirinzi, Giuseppina Martella

Summary: Strong evidence suggests that the decline in mitochondrial function is correlated with degenerative diseases. Various types of neurodegenerative diseases, such as Huntington's chorea and Parkinson's disease, share mitochondrial bioenergy dysregulation as a common feature. These diseases have different manifestations and genetic factors, but they both involve neuronal dysfunction and striatal impairment. This review focuses on describing the onset and development of both diseases in relation to mitochondrial dysfunction.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Psychology, Multidisciplinary

Huntington disease exacerbates action impulses

Shuhei Shiino, Nelleke Corine van Wouwe, Scott A. A. Wylie, Daniel O. O. Claassen, Katherine E. E. McDonell

Summary: This study investigated the temporal dynamics of action impulse control in Huntington disease (HD) patients using an inhibitory action control task. The results showed that HD patients had slower and less accurate reactions, as well as an exacerbated interference effect. However, they still preserved the ability to suppress impulsivity.

FRONTIERS IN PSYCHOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

A case of Huntington disease-like 2 in a patient of African ancestry: the everlasting support of clinical examination in the molecular era

Federica Ruscitti, Paola Origone, Giulia Rosti, Lucia Trevisan, Roberta Marchese, Andrea Brugnolo, Federico Massa, Paola Castellini, Paola Mandich

Summary: Huntington's disease (HD) and HD phenocopies share symptoms such as chorea, cognitive decline, and psychiatric symptoms. This study describes the first reported case of Huntington disease-like 2 (HDL2) in Italy, which is clinically and radiologically indistinguishable from HD, emphasizing the importance of considering African ancestry in the diagnostic process.

CLINICAL CASE REPORTS (2022)

添加到收藏夹

Article Medicine, General & Internal

Neural Network Aided Detection of Huntington Disease

Gerardo Alfonso Perez, Javier Caballero Villarraso

Summary: This paper presents an approach to identify Huntington Disease patients using DNA CpG methylation data and non-linear techniques. By selecting specific CpG sites and employing methods like artificial neural networks, the approach accurately distinguishes between control and HD patients.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Editorial Material Cell Biology

Hunting out the autophagic problem in Huntington disease

Karolina Pircs, Roger A. Barker, Johan Jakobsson

Summary: Huntington disease is a genetic neurodegenerative disorder that affects cells in the brain, with the underlying mechanism still unresolved. Recent research suggests that dysfunction in macroautophagic/autophagic pathways may contribute to cellular dysfunction and death.

AUTOPHAGY (2022)

添加到收藏夹

Article Chemistry, Organic

Photoredox Cyanomethylation of Indoles: Catalyst Modification and Mechanism

Connor J. O'Brien, Daniel G. Droege, Alexander Y. Jiu, Shivaani S. Gandhi, Nick A. Paras, Steven H. Olson, Jay Conrad

JOURNAL OF ORGANIC CHEMISTRY (2018)

添加到收藏夹

Article Chemistry, Medicinal

Selective Inhibitors of the Mutant B-Raf Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline

Adrian L. Smith, Frenel F. DeMorin, Nick A. Paras, Qi Huang, Jeffrey K. Petkus, Elizabeth M. Doherty, Thomas Nixey, Joseph L. Kim, Douglas A. Whittington, Linda F. Epstein, Matthew R. Lee, Mark J. Rose, Carol Babij, Manory Fernando, Kristen Hess, Quynh Le, Pedro Beltran, Josette Carnahan

JOURNAL OF MEDICINAL CHEMISTRY (2009)

添加到收藏夹

Article Chemistry, Organic

Convenient Route to Secondary Sulfinates: Application to the Stereospecific Synthesis of α-C-Chiral Sulfonamides

Michael G. Johnson, Michael W. Gribble, Jonathan B. Houze, Nick A. Paras

ORGANIC LETTERS (2014)

添加到收藏夹

Article Chemistry, Organic

A process for the rapid removal of dialkylamino-substituents from aromatic rings. Application to the expedient synthesis of (R)-tolterodine

Nick A. Paras, Bryon Simmons, David W. C. MacMillan

TETRAHEDRON (2009)

添加到收藏夹

Article Oncology

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Sean Caenepeel, Sean P. Brown, Brian Belmontes, Gordon Moody, Kathleen S. Keegan, Danny Chui, Douglas A. Whittington, Xin Huang, Leszek Poppe, Alan C. Cheng, Mario Cardozom, Jonathan Houze, Yunxiao Li, Brian Lucas, Nick A. Paras, Xianghong Wang, Joshua P. Taygerly, Marc Vimolratana, Manuel Zancanella, Liusheng Zhu, Elaina Cajulis, Tao Osgood, Jan Sun, Leah Damon, Regina K. Egan, Patricia Greninger, Joseph D. McClanaghan, Jianan Gong, Donia Moujalled, Giovanna Pomilio, Pedro Beltran, Cyril H. Benes, Andrew W. Roberts, David C. Huang, Andrew Wei, Jude Canon, Angela Coxon, Paul E. Hughes

CANCER DISCOVERY (2018)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of 4-Piperazine Isoquinoline Derivatives as Potent and Brain-Permeable Tau Prion Inhibitors with CDK8 Activity

Jean-Marc M. Grandjean, Alexander Y. Jiu, John W. West, Atsushi Aoyagi, Daniel G. Droege, Manuel Elepano, Makoto Hirasawa, Masakazu Hirouchi, Ryo Murakami, Joanne Lee, Koji Sasaki, Shimpei Hirano, Takao Ohyama, Benjamin C. Tang, Roy J. Vaz, Masahiro Inoue, Steven H. Olson, Stanley B. Prusiner, Jay Conrad, Nick A. Paras

ACS MEDICINAL CHEMISTRY LETTERS (2020)

添加到收藏夹

Article Chemistry, Organic

Water-Soluble Iridium Photoredox Catalyst for the Trifluoromethylation of Biomolecule Substrates in Phosphate Buffered Saline Solvent

Terrence-Thang H. Nguyen, Connor J. O'Brien, Minh L. N. Tran, Steven H. Olson, Nicholas S. Settineri, Stanley B. Prusiner, Nick A. Paras, Jay Conrad

Summary: The development of a water-soluble iridium catalyst enables the trifluoromethylation of polar small molecules and peptides in DMSO solution or aqueous media, providing up to 60% CF3- peptide. This reaction was optimized in a microtiter plate format under ambient air, using commercial Langlois reagent as a CF3 radical source and blue LEDs for excitation.

ORGANIC LETTERS (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Silver Benzoate Facilitates the Copper-Catalyzed C-N Coupling of Iodoazoles with Aromatic Nitrogen Heterocycles

Cedric Lozano, Cristian Ramirez, Ny Sin, Helene M-F Viart, Stanley B. Prusiner, Nick A. Paras, Jay Conrad

Summary: Traditional C-N coupling methods for the reaction of iodo-oxazole with 2-pyridinone was found to be low yielding, but yield can be improved by adding silver benzoate additives, CuI catalysts, and specific ligands. This method is applicable for the coupling of various iodo-heterocycles with 2-pyridinone, as well as for coupling NH-containing heterocycles with 4-iodooxazole.

ACS OMEGA (2021)

添加到收藏夹

Article Biology

A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons

Gha-Hyun J. Kim, Han Mo, Harrison Liu, Zhihao Wu, Steven Chen, Jiashun Zheng, Xiang Zhao, Daryl Nucum, James Shortland, Longping Peng, Mannuel Elepano, Benjamin Tang, Steven Olson, Nick Paras, Hao Li, Adam R. Renslo, Michelle R. Arkin, Bo Huang, Bingwei Lu, Marina Sirota, Su Guo

Summary: Parkinson's disease is a neurodegenerative disorder with no effective treatments currently available. However, research suggests that Renin-Angiotensin-Aldosterone System (RAAS) inhibitors may be beneficial in treating and delaying the progression of the disease by restoring mitochondrial function to protect dopamine-producing neurons. Further studies and improvements in these drugs are needed to explore and capitalize on their potential benefits.

ELIFE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Different α-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy

Jacob I. Ayers, Joanne Lee, Octovia Monteiro, Amanda L. Woerman, Ann A. Lazar, Carlo Condello, Nick A. Paras, Stanley B. Prusiner

Summary: Alpha-synuclein protein, with different conformations, is associated with neurodegenerative diseases including multiple system atrophy, dementia with Lewy bodies, and Parkinson's disease. Through experimental studies using transgenic mice and cultured cells, different strains of alpha-synuclein prions are found to be responsible for these diseases.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Stacked binding of a PET ligand to Alzheimer's tau paired helical filaments

Gregory E. E. Merz, Matthew J. J. Chalkley, Sophia K. K. Tan, Eric Tse, Joanne Lee, Stanley B. B. Prusiner, Nick A. A. Paras, William F. F. DeGrado, Daniel R. R. Southworth

Summary: The accumulation of tau protein aggregates in the brain is a characteristic feature of Alzheimer's disease and other neurodegenerative tauopathies, and understanding the mode of small-molecule binding to these aggregates is critical for diagnosis and treatment. The authors used cryo-electron microscopy to determine the structure of AD patient-derived tau filaments bound to the PET ligand GTP-1, revealing a stacked binding motif that may aid in the design of diagnostics and therapeutics. This study provides insight into the development of compounds targeting different amyloid folds found in neurodegenerative diseases.

NATURE COMMUNICATIONS (2023)

添加到收藏夹

Article Computer Science, Artificial Intelligence

Trans-channel fluorescence learning improves high-content screening for Alzheimer's disease therapeutics

Daniel R. Wong, Jay Conrad, Noah R. Johnson, Jacob Ayers, Annelies Laeremans, Joanne C. Lee, Jisoo Lee, Stanley B. Prusiner, Sourav Bandyopadhyay, Atul J. Butte, Nick A. Paras, Michael J. Keiser

Summary: This study develops a deep learning method for generating images in drug discovery, with broad applicability across diverse fluorescence microscopy datasets.

NATURE MACHINE INTELLIGENCE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Expanding spectrum of prion diseases

Jacob Ayers, Nick A. Paras, Stanley B. Prusiner

EMERGING TOPICS IN LIFE SCIENCES (2020)

添加到收藏夹

Article Chemistry, Organic

Selectivity in the Addition of Electron-Deficient Radicals to the C2 Position of Indoles

Yi Li, Roy J. Vaz, Steven H. Olson, Mark Munson, Nick A. Paras, Jay Conrad

EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2020)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.